PRESTALIA combines two key hypertensive agents, perindopril arginine and amlodipine besylate, and is indicated for first-line treatment of hypertension. Lowering blood pressure may prevent heart attack, stroke, or death. PRESTALIA has been shown to reduce these events beyond simply lowering blood pressure.3 Both perindopril and calcium channel blockers (such as amlodipine) have been proven to reduce cardiac events and total mortality by 46%.3
Welcome to PrestaliaDirect, the easiest path to blood pressure control. PrestaliaDirect helps you and your doctor monitor and manage your blood pressure. Your medication is shipped directly to your home, so you won’t run out again. And if you order our free blood pressure monitor, you can share your results online with your doctor.
Create your account through our registration portal and start your membership today. Or contact our call center–we’re always happy to help.
Find a Rep
Have questions about PRESTALIA or the PrestaliaDirect program? Want to be part of our pharmacy network? Looking for a PRESTALIA representative in your area? Adhera Therapeutics reps are organized by geographic region. Simply click the email link below to contact a customer service representative. We will respond within 24 hours.
Or just call us directly. We’re here to answer all of your questions.
4721 Emperor Boulevard, Ste. 350, Durham, NC 27702
- PRESTALIA (perindopril arginine and amlodipine) Tablets [package insert]. Durham, NC; Adhera Therapeutics, Inc. 2018.
- Prestalia Full Prescribing Information. https://prestalia-us.net/package-insert
- Bertrand ME, Ferrari R, Remme WJ, et al; EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010;159(5):795-802.
- The Lancet Publishing Group: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Angio-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. In: www.thelancet.com, Vol. 361, No. 9364, p1149-1158 [Internet]. 2003 Apr 5 – [cited 2016 Jun 15] Available from http:thelancet.com/journals/lancet/article/P1150140-6736(03)12948-0/abstract.